PEX13

Across TCGA pan-cancer cohorts, PEX13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PEX13 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PEX13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PEX13 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where PEX13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	7	view →
CCRCC	DFS	Quartile	III,IV	0.621	1.000	.031	6	view →
LUAD	OS	Median	II,III,IV	0.799	0.465	.038	3	view →
GBM	DFS	Quartile	All	0.694	0.365	.002	2	view →
PDAC	DFS	Median	III,IV	0.247	0.525	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PEX13–LSCC (DFS)

Open the LSCC breakdown →